Name: Global Photodynamic Therapy Market Size and Analysis 2035
Creator: Roots Analysis
Published: 2026-02-04T00:00:01+05:30
License: https://www.rootsanalysis.com/privacy.html
Keywords: Photodynamic Therapy Market, Photodynamic Therapy Market Growth, Photodynamic Therapy Market Trends, Photodynamic Therapy Market Size, Photodynamic Therapy Market Share, Photodynamic Therapy Market Analysis, Photodynamic Therapy Market Forecast, Photodynamic Therapy Market Report, Global Photodynamic Therapy Market, Photodynamic Therapy Industry

Market Outlook

The global photodynamic therapy market, valued at USD 672 million in 2025, is projected to reach USD 749 million in 2026 and USD 1,532 million by 2035, representing a CAGR of 8.3% during the forecast period 2026 to 2035.

Global Photodynamic Therapy Market Growth 2026 to 2035

See What’s in the Full Report - Request Your Complimentary Insights!

Market Report: Key Takeaways

Market Size & Trends

In terms of target indication, actinic keratosis holds the highest share (over 35%) of the market.
With respect to therapeutic areas, oncological disorders dominate the current market.
In terms of key geographical regions, Europe holds the highest share (nearly 50%) of the market.

Key Market Statistics

Market Size in 2026: $749 Million
Estimated Market Size in 2035: $1,532 Million
CAGR (2026-2035): 8.3%
Europe: Largest market in 2026
North America: Fastest growing region

Market Introduction

Light activated therapy / photodynamic therapy (PDT) is a targeted, minimally invasive treatment modality. It utilizes photosensitizing agents activated by specific light wavelengths to produce cytotoxic reactive oxygen species, enabling selective destruction of cancer cells and pathological tissues. Notably, the concept of light activated therapy / photodynamic therapy originated in the early 20th century and has been refined through decades of clinical research. It is worth mentioning that PDT has evolved into a versatile treatment option for oncological disorders, offering advantages such as reduced systemic toxicity compared to traditional chemotherapy and radiotherapy. Further, advancements in photosensitizer design, such as porphyrin-based conjugates and nanoparticle formulations combined with precision light-delivery devices, have expanded PDT's role beyond cancer treatment to antimicrobial applications.

In photodynamic therapy, photosensitizers are administered locally at tumor sites, minimizing systemic exposure and reducing complications such as prolonged skin photosensitivity and off-target effects. Further, this approach has also shown positive outcomes in treating skin conditions such as actinic keratosis, acne, warts and microvesicles, making it ideal for the treatment of broad range of skin conditions.

Given the various benefits of light activated therapies, several industrial stakeholders have undertaken various initiatives to develop effective photoimmunotherapies / photodynamic therapies against multiple target indications. It is important to highlight here that over 70 therapies are currently under clinical development and multiple photodynamic therapies have already received approval. Moreover, several key players are focusing on leveraging nanotechnology such as quantum dots as advanced photosensitizers to treat skin cancer. Owing to the ongoing advancements and rising research on these therapies, the photodynamic therapy market is likely to witness significant market growth during the forecast period.

Market Segmentation

Based on the research, we have segmented the Photodynamic Therapy Market Report into target indication, therapeutic area and key geographical regions.

By Target Indication

Actinic Keratosis
Prostate Cancer
Age-related Macular Degeneration
Head and Neck Squamous Cell Carcinoma
Basal Cell Carcinoma
Port Wine Stain
Barrett’s Esophagus
Esophageal Cancer
Endobronchial Cancer
Lung Cancer
Bowen’s Disease
Brain Cancer
Bladder Cancer
T-cell Lymphoma
Urothelial Cancer

By Therapeutic Area

Oncological Disorders
Dermatological Disorders
Ophthalmic Disorders

By Key Geographical Regions

North America
- US
- Canada

Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe

Asia-Pacific
- China
- Japan
- India

Middle East and North Africa
- Israel

Want Information on Specific Region / Segment?

Photodynamic Therapy Market Key Insights

What are the Latest Photodynamic Therapy Market Trends?

Rising Incidence of Cancer: With the growing incidence of skin cancer globally, there is an increase in demand for effective and minimal invasive treatment such as light activated therapies. According to American Cancer Society, there were 104,960 new cases of skin cancer reported in 2025 in the US alone, with high recurrence rates. For instance, basal cell carcinoma has shown a recurrence rate of 10% and some rare skin cancers have recurrence rate of 40%.

Notably, light activated therapy addresses this challenge by utilizing topical photosensitizers that selectively eradicate precancerous actinic keratosis and early non-melanoma skin cancers (NMSCs), thereby driving growing demand for these therapies in skin cancer treatment. In addition, researchers are also exploring the use of light-activated therapy in other hard-to-treat cancers, including advanced stomach cancer. They have developed an innovative light-activated immunotherapy, that uses specially engineered proteins called betabodies, which are injected into the abdomen and selectively bind to cancer cells while sparing healthy tissue.

Increase in Clinical Trial Activity: Clinical trial activity in the photodynamic therapy market has seen a significant increase, driven by advancements in photosensitizers, light delivery systems, and combination therapies targeting oncological and dermatological disorders. Notably, majority of the registered trials are focused on solid tumors such as glioblastoma, esophageal cancer, and non-melanoma skin cancers, while expanding into antimicrobial PDT applications for infectious diseases.

Your Business is Unique – Why Shouldn’t Your Report Be?

What are the Key Drivers for Market Growth?

The photodynamic therapy market growth is driven by various factors, including the rising global incidence of cancer and dermatological disorders, which drives demand for targeted, minimally invasive treatments that leverage photosensitizers and light activation for precise tumor ablation with fewer systemic toxicities. Further, advancements in photosensitizer formulations and light delivery devices, such as improved diode laser and fiber optics enhance therapeutic efficacy through deeper tissue penetration for better oncology outcomes. Moreover, increasing regulatory approvals for PDT in antimicrobial applications and age-related macular degeneration (AMD), alongside supportive reimbursement policies have also accelerated clinical adoption of light activated therapies. Notably, photobiomodulation, a form of light therapy that utilizes non-ionizing forms of light sources including lasers, LEDs, and broadband light is the first non-invasive treatment authorized by the US Food and Drug Administration (USFDA) for use in treating dry AMD

Pay Only for What You Need – The Best Way to Optimize

Recent Developments in Photodynamic Therapy Market

In January 2026, Ferring Pharmaceuticals entered into a clinical development agreement with Theralase Technologies. The agreement builds on Theralase’s existing clinical program with a new cohort investigating its investigational light-activated small molecule Ruvidar (TLD-1433) in combination with Ferring’s intravesical non-replicating gene therapy ADSTILADRIN.
In June 2025, Biofrontera entered into a strategic partnership in order to acquire all the US assets associated with Ameluz and RhodoLED, including New Drug Application (NDA) and associated patents from Germany-based Biofrontera.
In May 2025, Sun Pharmaceutical announced that the USFDA has granted premarket approval application (PMA) approval to its next generation of BLU-U Blue Light Photodynamic Therapy Illuminator. The new model (LED BLU-U) in combination with LEVULAN KERASTICK (aminolevulinic acid HCl) is recommended for the treatment of actinic keratoses.
In June 2025, physicians at the LV Prasad Eye Institute evaluated a new photodynamic therapy, PDAT-RB, for treating a rare eye infection called acanthamoeba keratasis. This therapy uses a dye called rose Bengal, which is activated by light to produce powerful molecules that effectively combat the pathogen.

Will Oncological Disorder Segment Hold the Highest Share in the Future?

In 2026, the oncological disorders segment occupies the highest photodynamic therapy market share (close to 50%) and is likely to grow at a higher CAGR (11%) during the forecast period.
This is driven by the rising global incidence of cancer, especially skin, lung, esophageal, and head-and-neck cancer, which has fueled the demand for PDT due to its targeted mechanism of selectively destroying malignant cells through light-activated photosensitizers.

Global Photodynamic Therapy Market Share by Therapeutic Area, 2026

Which Target Indication Accounts for the Largest Photodynamic Therapy Market Share?

In 2026, the actinic keratosis segment occupies higher market light activated therapy size (with over 35% share). This dominance is due to the rising prevalence of actinic keratosis, a precancerous skin condition linked to chronic UV exposure, along with PDT’s enhanced cosmetic outcomes compared to cryotherapy.
It is worth highlighting that the market share for head and neck squamous cell carcinoma is likely to grow at a relatively higher CAGR, during the forecast period. This is likely due to its rising global incidence, along with clinical advancements such as PDT combinations with immunotherapies, which show promising response rates and reduced severe toxicities.

Get an Instant Quote in 10 Minutes. Lowest Price Guaranteed

Regional Analysis: Which Regions are Showing the Fastest Growth in Light Activated Therapy Industry?

Europe: Dominating the Market by Securing Highest Share

According to our photodynamic therapy market forecast, Europe is likely to capture the highest share (nearly 50%) in 2026. Europe's dominance is due to the high prevalence of non-melanoma skin cancers like actinic keratosis and basal cell carcinoma, which affect 20% of citizens annually, driving demand for PDT. Further, robust healthcare systems in Germany, France, and the UK support widespread outpatient PDT adoption, bolstered by national guidelines, reimbursement policies and ongoing trials for oncological and dermatological indications.

North America: An Emerging Growth Spot

The market in North America is likely to grow at the highest CAGR (14%), during the forecast period till 2035, as per our photodynamic therapy market analysis. This growth is due to the rapid digital transformation, expanding pharmaceutical R&D investments, and strong government initiatives to modernize healthcare infrastructure in this region.

Global Photodynamic Therapy Market Share by Geographical Regions, 2026

Scope of Photodynamic Therapy Market Report

Key Report Attribute	Details
Historical Trend	Since 2021
Forecast Period	Till 2035
Market Size 2026	$ 749 Million
Market Size 2035	$ 1,532 Million
CAGR (Till 2035)	8.3%
Segments Covered	Target Indication Therapeutic Area Key Geographical Regions
Key Players Profiled	ADVANZ PHARMA Biofrontera Biolitec Pharma Galderma Luzitin Nanospectra Biosciences Novartis Rakuten Medical Impact Biotech Theralase (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization
Excel Data Packs (Complimentary)	Available

+ 1. PREFACE

1.1. Introduction

1.2. Market Share Insights

1.3. Key Market Insights

1.4. Report Coverage

1.5. Key Questions Answered

1.6. Chapter Outlines

+ 2. RESEARCH METHODOLOGY

2.1. Chapter Overview

2.2. Research Assumptions

2.2.1. Market Landscape and Market Trends

2.2.2. Market Forecast and Opportunity Analysis

2.2.3. Comparative Analysis

2.3. Database Building

2.3.1. Data Collection

2.3.2. Data Validation

2.3.3. Data Analysis

2.4. Project Methodology

2.4.1. Secondary Research

2.4.1.1. Annual Reports

2.4.1.2. Academic Research Papers

2.4.1.3. Company Websites

2.4.1.4. Investor Presentations

2.4.1.5. Regulatory Filings

2.4.1.6. White Papers

2.4.1.7. Industry Publications

2.4.1.8. Conferences and Seminars

2.4.1.9. Government Portals

2.4.1.10. Media and Press Releases

2.4.1.11. Newsletters

2.4.1.12. Industry Databases

2.4.1.13. Roots Proprietary Databases

2.4.1.14. Paid Databases and Sources

2.4.1.15. Social Media Portals

2.4.1.16. Other Secondary Sources

2.4.2. Primary Research

2.4.2.1. Types of Primary Research

2.4.2.1.1. Qualitative Research

2.4.2.1.2. Quantitative Research

2.4.2.1.3. Hybrid Approach

2.4.2.2. Advantages of Primary Research

2.4.2.3. Techniques for Primary Research

2.4.2.3.1. Interviews

2.4.2.3.2. Surveys

2.4.2.3.3. Focus Groups

2.4.2.3.4. Observational Research

2.4.2.3.5. Social Media Interactions

2.4.2.4. Key Opinion Leaders Considered in Primary Research

2.4.2.4.1. Company Executives (CXOs)

2.4.2.4.2. Board of Directors

2.4.2.4.3. Company Presidents and Vice Presidents

2.4.2.4.4. Research and Development Heads

2.4.2.4.5. Technical Experts

2.4.2.4.6. Subject Matter Experts

2.4.2.4.7. Scientists

2.4.2.4.8. Doctors and Other Healthcare Providers

2.4.2.5. Ethics and Integrity

2.4.2.5.1. Research Ethics

2.4.2.5.2. Data Integrity

2.4.3. Analytical Tools and Databases

2.5. Robust Quality Control

+ 3. MARKET DYNAMICS

3.1. Chapter Overview

3.2. Forecast Methodology

3.2.1. Top-down Approach

3.2.2. Bottom-up Approach

3.2.3. Hybrid Approach

3.3. Market Assessment Framework

3.3.1. Total Addressable Market (TAM)

3.3.2. Serviceable Addressable Market (SAM)

3.3.3. Serviceable Obtainable Market (SOM)

3.3.4. Currently Acquired Market (CAM)

3.4. Forecasting Tools and Techniques

3.4.1. Qualitative Forecasting

3.4.2. Correlation

3.4.3. Regression

3.4.4. Extrapolation

3.4.5. Convergence

3.4.6. Sensitivity Analysis

3.4.7. Scenario Planning

3.4.8. Data Visualization

3.4.9. Time Series Analysis

3.4.10. Forecast Error Analysis

3.5. Key Considerations

3.5.1. Demographics

3.5.2. Government Regulations

3.5.3. Reimbursement Scenarios

3.5.4. Market Access

3.5.5. Supply Chain

3.5.6. Industry Consolidation

3.5.7. Pandemic / Unforeseen Disruptions Impact

3.6. Limitations

+ 4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview

4.2. Market Dynamics

4.2.1. Time Period

4.2.1.1. Historical Trends

4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage

4.2.2.1. Major Currencies Affecting the Market

4.2.2.2. Factors Affecting Currency Fluctuations on the Industry

4.2.2.3. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Currency Exchange Rate

4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market

4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession

4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt

4.2.5. Inflation

4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy

4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates

4.2.6.1. Interest Rates and Their Impact on the Market

4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis

4.2.7.1. Type of Commodity

4.2.7.2. Origins and Destinations

4.2.7.3. Values and Weights

4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics

4.2.8.1. Import Scenario

4.2.8.2. Export Scenario

4.2.8.3. Trade Policies

4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers

4.2.8.5. Impact of Trade Barriers on the Market

4.2.9. War Impact Analysis

4.2.9.1. Russian-Ukraine War

4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors

4.2.10.1. Global Economic Impact

4.2.10.2. Industry-specific Impact

4.2.10.3. Government Response and Stimulus Measures

4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators

4.2.11.1. Fiscal Policy

4.2.11.2. Consumer Spending

4.2.11.3. Gross Domestic Product

4.2.11.4. Employment

4.2.11.5. Taxes

4.2.11.6. Stock Market Performance

4.2.11.7. Cross Border Dynamics

4.3. Conclusion

+ 5. EXECUTIVE SUMMARY

+ 6. INTRODUCTION

6.1. Overview of Light Activated Therapies

6.2. Types of Light Activated Therapies

6.3. Components of Light Activated Therapies

6.3.1. Photosensitizing Substance

6.3.2. Light Source and Device

6.4. Type of Light Activated Therapy

6.4.1. Photoimmunotherapy

6.4.1.1. Mechanism of Action of Photoimmunotherapies

6.4.2. Photodynamic Therapy

6.4.2.1. Mechanism of Action of Photodynamic Therapy

6.4.2.2. Advantages and Challenges Associated with Photodynamic Therapy

6.4.3. Photothermal Therapy

6.4.3.1. Mechanism of Action of Photothermal Therapy

6.5. Difference between Photodynamic and Photothermal Therapy

6.6. Advantages of Light Activated Therapies

+ 7. MARKET LANDSCAPE

7.1. Chapter Overview

7.2. Light Activated Therapies: Overall Market Landscape

7.2.1. Analysis by Type of Light Activated Therapy

7.2.2. Analysis by Stage of Development

7.2.3. Analysis by Type of Light Used

7.2.4. Analysis by Type of Therapy

7.2.5. Analysis by Dosing Frequency

7.2.6. Analysis by Target Indication

7.2.7. Analysis by Therapeutic Area

7.2.8. Analysis by Therapeutic Area and Stage of Development

7.3. Light Activated Therapy Developers: Overall Market Landscape

7.3.1. Analysis by Year of Establishment

7.3.2. Analysis by Company Size

7.3.3. Analysis by Location of Headquarters (Region)

7.3.4. Analysis by Location of Headquarters (Country)

+ 8. COMPANY AND DRUG PROFILES

8.1. Chapter Overview

8.2. ADVANZ PHARMA

8.2.1. Company Overview

8.2.2. Financial Information

8.2.3. Product Portfolio

8.2.4. Recent Developments and Future Outlook

8.3. Biofrontera

8.4. biolitec Pharma

8.5. Luzitin

8.6. Nanospectra Biosciences

8.7. photoatomic

8.8. Rakuten Medical

8.9. Impact Biotech

8.10. Theralase

8.11. Cetuximab Sarotalocan®

8.11.1. Company Overview

8.11.2. Drug Overview

8.11.3. Clinical Development Status

8.11.4. Clinical Trial Endpoints

8.11.5. Dosage Regimen

8.11.6. Key Insights

8.11.7. Sales Revenue

8.12. Alacare®

8.12.1. Company Overview

8.12.2. Drug Overview

8.12.3. Clinical Development Status

8.12.4. Clinical Trial Endpoints

8.12.5. Dosage Regimen

8.12.6. Key Insights

8.12.7. Sales Revenue

8.13. Ameluz®

8.13.1. Company Overview

8.13.2. Drug Overview

8.13.3. Clinical Development Status

8.13.4. Dosage Regimen

8.13.5. Key Insights

8.13.6. Sales Revenue

8.14. Aminolevulinic Acid

8.14.1. Company Overview

8.14.2. Drug Overview

8.14.3. Clinical Development Status

8.14.4. Key Insights

8.14.5. Sales Revenue

8.15. Foscan® (Temoporfin)

8.15.1. Company Overview

8.15.2. Drug Overview

8.15.3. Clinical Development Status

8.15.4. Clinical Trial Endpoints

8.15.5. Dosage Regimen

8.15.6. Key Insights

8.15.7. Sales Revenue

8.16. FuMeiDa® (Hemoporfin)

8.16.1. Company Overview

8.16.2. Drug Overview

8.16.3. Clinical Development Status

8.16.4. Clinical Trial Endpoints

8.16.5. Dosage Regimen

8.16.6. Key Insights

8.16.7. Sales Revenue

8.17. Levulan Kerastick®

8.17.1. Company Overview

8.17.2. Drug Overview

8.17.3. Clinical Development Status

8.17.4. Dosage Regimen

8.17.5. Key Insights

8.17.6. Sales Revenue

8.18. Metvixia® (Metvix)

8.18.1. Company Overview

8.18.2. Drug Overview

8.18.3. Clinical Development Status

8.18.4. Clinical Trial Endpoints

8.18.5. Dosage Regimen

8.18.6. Key Insights

8.18.7. Sales Revenue

8.19. Porfimer Sodium / Photofrin®

8.19.1. Company Overview

8.19.2. Drug Overview

8.19.3. Clinical Development Status

8.19.4. Clinical Trial Endpoints

8.19.5. Dosage Regimen

8.19.6. Sales Revenue

8.20. Verteporfin® (Visudyne)

8.20.1. Company Overview

8.20.2. Drug Overview

8.20.3. Clinical Development Status

8.20.4. Clinical Trial Endpoints

8.20.5. Dosage Regimen

8.20.6. Key Insights

8.20.7. Sales Revenue

+ 9. CLINICAL TRIAL ANALYSIS

9.1. Chapter Overview

9.2. Scope and Methodology

9.3. Light Activated Therapies: Clinical Trial Analysis

9.3.1. Analysis by Trial Registration Year

9.3.2. Analysis of Patients Enrolled by Trial Registration Year

9.3.3. Analysis by Trial Phase

9.3.4. Analysis of Patients Enrolled by Trial Phase

9.3.5. Analysis by Trial Status

9.3.6. Analysis by Trial Registration Year and Trial Status

9.3.7. Analysis of Patients Enrolled by Trial Status

9.3.8. Analysis by Target Patient Population

9.3.9. Analysis by Patient Gender

9.3.10. Analysis by Type of Sponsor / Collaborator

9.3.11. Analysis by Study Design

9.3.11.1. Analysis by Type of Patient Allocation Model Used

9.3.11.2. Analysis by Type of Trial Masking Adopted

9.3.11.3. Analysis by Type of Trial Intervention Model

9.3.11.4. Analysis by Trial Purpose

9.3.12. Most Active Players: Analysis by Number of Clinical Trials

9.3.13. Analysis by Geography

9.3.13.1. Analysis of Clinical Trials by Geography

9.3.13.2. Analysis of Clinical Trials by Geography and Trial Status

9.3.13.3. Analysis of Clinical Trials by Geography and Trial Phase

9.3.13.4. Analysis of Patients Enrolled by Geography

9.3.13.5. Analysis of Patients Enrolled by Geography and Trial Status

+ 10. PATENT ANALYSIS

10.1. Chapter Overview

10.2. Scope and Methodology

10.3. Light Activated Therapies: Patent Analysis

10.3.1. Analysis by Type of Patent

10.3.2. Analysis by Publication Year

10.3.3. Analysis by Type of Patent and Publication Year

10.3.4. Analysis by Application Year

10.3.5. Analysis by Jurisdiction

10.3.6. Analysis by Type of Applicant

10.3.7. Analysis by Patent Age

10.3.8. Analysis by CPC Symbols

10.3.9. Leading Industry Players: Analysis by Number of Patents

10.3.10. Leading Non-Industry Players: Analysis by Number of Patents

10.3.11. Leading Inventors: Analysis by Number of Patents

10.4. Light Activated Therapies: Patent Benchmarking Analysis

10.4.1. Analysis by Patent Characteristics

10.4.2. Analysis by Leading Industry Players

10.5. Patent Valuation Analysis

+ 11. MARKET IMPACT ANALYSIS

11.1. Chapter Overview

11.2. Market Drivers

11.3. Market Restraints

11.4. Market Opportunities

11.5. Market Challenges

11.6. Conclusion

+ 12. GLOBAL PHOTODYNAMIC THERAPY MARKET

12.1. Chapter Overview

12.2. Key Assumptions and Methodology

12.3. Global Photodynamic Therapy Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

12.3.1. Roots Analysis Perspective on Market Growth

12.3.2. Scenario Analysis

12.3.2.1. Conservative Scenario

12.3.2.2. Optimistic Scenario

12.4. Key Market Segmentations

+ 13. PHOTODYNAMIC THERAPY MARKET, BY TARGET INDICATION

13.1. Chapter Overview

13.2. Key Assumptions and Methodology

13.3. Photodynamic Therapy Market: Distribution by Target Indication

13.3.1. Photodynamic Therapy Market for Actinic Keratosis, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.2. Photodynamic Therapy Market for Prostate Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.3. Photodynamic Therapy Market for Age-related Macular Degeneration, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.4. Photodynamic Therapy Market for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.5. Photodynamic Therapy Market for Basal Cell Carcinoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.6. Photodynamic Therapy Market for Port Wine Stain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.7. Photodynamic Therapy Market for Barrett’s Esophagus, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.8. Photodynamic Therapy Market for Esophageal Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.9. Photodynamic Therapy Market for Endobronchial Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.10. Photodynamic Therapy Market for Lung Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.11. Photodynamic Therapy Market for Bowen’s Disease, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.12. Photodynamic Therapy Market for Brain Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.13. Photodynamic Therapy Market for Bladder Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.14. Photodynamic Therapy Market for T-cell Lymphoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.3.15. Photodynamic Therapy Market for Urothelial Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

13.4. Data Triangulation and Validation

+ 14. PHOTODYNAMIC THERAPY MARKET, BY THERAPEUTIC AREA

14.1. Chapter Overview

14.2. Key Assumptions and Methodology

14.3. Photodynamic Therapy Market: Distribution by Therapeutic Area

14.3.1. Photodynamic Therapy Market for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

14.3.2. Photodynamic Therapy Market for Dermatological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

14.3.3. Photodynamic Therapy Market for Ophthalmic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

14.4. Data Triangulation and Validation

+ 15. PHOTODYNAMIC THERAPY MARKET, BY KEY GEOGRAPHICAL REGIONS

15.1. Chapter Overview

15.2. Key Assumptions and Methodology

15.3. Photodynamic Therapy Market: Distribution by Key Geographical Regions

15.3.1. Photodynamic Therapy Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.1.1. Photodynamic Therapy Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.1.2. Photodynamic Therapy Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.2. Photodynamic Therapy Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.2.1. Photodynamic Therapy Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.2.2. Photodynamic Therapy Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.2.3. Photodynamic Therapy Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.2.4. Photodynamic Therapy Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.2.5. Photodynamic Therapy Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.2.6. Photodynamic Therapy Market in Rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.3. Photodynamic Therapy Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.3.1. Photodynamic Therapy Market in India, Forecasted Estimates (till 2035)

15.3.3.2. Photodynamic Therapy Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.3.3. Photodynamic Therapy Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.4. Photodynamic Therapy Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

15.3.4.1. Photodynamic Therapy Market in Israel, Forecasted Estimates (till 2035)

15.4. Market Dynamics Assessment: Key Geographical Regions

15.4.1. Penetration Growth (P-G) Matrix

15.4.2. Market Movement Analysis

15.5. Data Triangulation and Validation

+ 16. CONCLUDING REMARKS

+ 17. EXECUTIVE INSIGHTS

+ 18. APPENDIX I: TABULATED DATA

+ 19. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHY

+ 20. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

20.1. Photodynamic Therapy Market in North America: Distribution by Target Indication

20.1.1. Photodynamic Therapy Market in North America for Actinic Keratosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.2. Photodynamic Therapy Market in North America for Prostate Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.3. Photodynamic Therapy Market in North America for Age-related Macular Degeneration, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.4. Photodynamic Therapy Market in North America for Head and Neck Squamous Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.5. Photodynamic Therapy Market in North America for Basal Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.6. Photodynamic Therapy Market in North America for Port Wine Stain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.7. Photodynamic Therapy Market in North America for Barrett’s Esophagus, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.8. Photodynamic Therapy Market in North America for Esophageal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.9. Photodynamic Therapy Market in North America for Endobronchial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.10. Photodynamic Therapy Market in North America for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.11. Photodynamic Therapy Market in North America for Bowen’s Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.12. Photodynamic Therapy Market in North America for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.13. Photodynamic Therapy Market in North America for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.14. Photodynamic Therapy Market in North America for T-cell Lymphoma Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.1.15. Photodynamic Therapy Market in North America for Urothelial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.2. Photodynamic Therapy Market in North America: Distribution by Therapeutic Area

20.2.1. Photodynamic Therapy Market in North America for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.2.2. Photodynamic Therapy Market in North America for Dermatological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

20.2.3. Photodynamic Therapy Market in North America for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ 21. MARKET OPPORTUNITY ANALYSIS: EUROPE

21.1. Photodynamic Therapy Market in Europe: Distribution by Target Indication

21.1.1. Photodynamic Therapy Market in Europe for Actinic Keratosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.2. Photodynamic Therapy Market in Europe for Prostate Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.3. Photodynamic Therapy Market in Europe for Age-related Macular Degeneration, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.4. Photodynamic Therapy Market in Europe for Head and Neck Squamous Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.5. Photodynamic Therapy Market in Europe for Basal Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.6. Photodynamic Therapy Market in Europe for Port Wine Stain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.7. Photodynamic Therapy Market in Europe for Barrett’s Esophagus, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.8. Photodynamic Therapy Market in Europe for Esophageal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.9. Photodynamic Therapy Market in Europe for Endobronchial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.10. Photodynamic Therapy Market in Europe for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.11. Photodynamic Therapy Market in Europe for Bowen’s Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.12. Photodynamic Therapy Market in Europe for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.13. Photodynamic Therapy Market in Europe for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.14. Photodynamic Therapy Market in Europe for T-cell Lymphoma Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.1.15. Photodynamic Therapy Market in Europe for Urothelial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.2. Photodynamic Therapy Market in Europe: Distribution by Therapeutic Area

21.2.1. Photodynamic Therapy Market in Europe for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.2.2. Photodynamic Therapy Market in Europe for Dermatological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

21.2.3. Photodynamic Therapy Market in Europe for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ 22. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

22.1. Photodynamic Therapy Market in Asia-Pacific: Distribution by Target Indication

22.1.1. Photodynamic Therapy Market in Asia-Pacific for Actinic Keratosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.2. Photodynamic Therapy Market in Asia-Pacific for Prostate Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.3. Photodynamic Therapy Market in Asia-Pacific for Age-related Macular Degeneration, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.4. Photodynamic Therapy Market in Asia-Pacific for Head and Neck Squamous Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.5. Photodynamic Therapy Market in Asia-Pacific for Basal Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.6. Photodynamic Therapy Market in Asia-Pacific for Port Wine Stain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.7. Photodynamic Therapy Market in Asia-Pacific for Barrett’s Esophagus, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.8. Photodynamic Therapy Market in Asia-Pacific for Esophageal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.9. Photodynamic Therapy Market in Asia-Pacific for Endobronchial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.10. Photodynamic Therapy Market in Asia-Pacific for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.11. Photodynamic Therapy Market in Asia-Pacific for Bowen’s Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.12. Photodynamic Therapy Market in Asia-Pacific for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.13. Photodynamic Therapy Market in Asia-Pacific for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.14. Photodynamic Therapy Market in Asia-Pacific for T-cell Lymphoma Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.1.15. Photodynamic Therapy Market in Asia-Pacific for Urothelial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.2. Photodynamic Therapy Market in Asia-Pacific: Distribution by Therapeutic Area

22.2.1. Photodynamic Therapy Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.2.2. Photodynamic Therapy Market in Asia-Pacific for Dermatological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

22.2.3. Photodynamic Therapy Market in Asia-Pacific for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ 23. MARKET OPPORTUNITY ANALYSIS: MIDDLE EAST AND NORTH AFRICA

23.1. Photodynamic Therapy Market in Middle East and North Africa: Distribution by Target Indication

23.1.1. Photodynamic Therapy Market in Middle East and North Africa for Actinic Keratosis, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.2. Photodynamic Therapy Market in Middle East and North Africa for Prostate Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.3. Photodynamic Therapy Market in Middle East and North Africa for Age-related Macular Degeneration, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.4. Photodynamic Therapy Market in Middle East and North Africa for Head and Neck Squamous Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.5. Photodynamic Therapy Market in Middle East and North Africa for Basal Cell Carcinoma, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.6. Photodynamic Therapy Market in Middle East and North Africa for Port Wine Stain, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.7. Photodynamic Therapy Market in Middle East and North Africa for Barrett’s Esophagus, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.8. Photodynamic Therapy Market in Middle East and North Africa for Esophageal Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.9. Photodynamic Therapy Market in Middle East and North Africa for Endobronchial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.10. Photodynamic Therapy Market in Middle East and North Africa for Lung Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.11. Photodynamic Therapy Market in Middle East and North Africa for Bowen’s Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.12. Photodynamic Therapy Market in Middle East and North Africa for Brain Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.13. Photodynamic Therapy Market in Middle East and North Africa for Bladder Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.14. Photodynamic Therapy Market in Middle East and North Africa for T-cell Lymphoma Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.1.15. Photodynamic Therapy Market in Middle East and North Africa for Urothelial Cancer, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.2. Photodynamic Therapy Market in Middle East and North Africa: Distribution by Therapeutic Area

23.2.1. Photodynamic Therapy Market in Middle East and North Africa for Oncological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.2.2. Photodynamic Therapy Market in Middle East and North Africa for Dermatological Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

23.2.3. Photodynamic Therapy Market in Middle East and North Africa for Ophthalmic Disorders, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

+ List of Figure

Figure 2.1 Research Methodology: Project Methodology

Figure 2.2 Research Methodology: Data Sources for Secondary Research

Figure 2.3 Research Methodology: Robust Quality Control

Figure 3.1 Market Dynamics: Forecast Methodology

Figure 3.2 Market Dynamics: Key Market Segmentation

Figure 4.1 Lessons Learnt from Past Recessions

Figure 5.1 Executive Summary: Overall Market Landscape

Figure 5.2 Executive Summary: Market Trends

Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis

Figure 6.1 Type of Light Activated Therapy

Figure 6.2 Mechanism of Action of Photoimmunotherapies

Figure 6.3 Mechanism of Action of Photodynamic Therapy

Figure 6.4 Advantages and Challenges associated with Photodynamic Therapy

Figure 6.5 Mechanism of Action of Photothermal Therapy

Figure 7.1 Light Activated Therapies: Distribution by Type of Light Activated Therapy

Figure 7.2 Light Activated Therapies: Distribution by Stage of Development

Figure 7.3 Light Activated Therapies: Distribution by Type of Light Used

Figure 7.4 Light Activated Therapies: Distribution by Type of Therapy

Figure 7.5 Light Activated Therapies: Distribution by Dosing Frequency

Figure 7.6 Light Activated Therapies: Distribution by Target Indication

Figure 7.7 Light Activated Therapies: Distribution by Therapeutic Area

Figure 7.8 Light Activated Therapies: Distribution by Therapeutic Area and Stage of Development

Figure 7.9 Light Activated Therapy Developers: Distribution by Year of Establishment

Figure 7.10 Light Activated Therapy Developers: Distribution by Company Size

Figure 7.11 Light Activated Therapy Developers: Distribution by Location of Headquarters (Region)

Figure 7.12 Light Activated Therapy Developers: Distribution by Location of Headquarters (Country)

Figure 8.1 ADVANZ PHARMA: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.2 Biofrontera: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.3 biolitec Pharma: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.4 Luzitin: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.5 Nanospectra Biosciences: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.6 photoatomic: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.7 Rakuten Medical: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.8 Impact Biotech: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.9 Theralase: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Figure 8.10 Cetuximab Sarotalocan®: Sales Revenue

Figure 8.11 Alacare®: Sales Revenue

Figure 8.12 Ameluz®: Sales Revenue

Figure 8.13 Aminolevulinic Acid: Sales Revenue

Figure 8.14 Foscan® (Temoporfin): Sales Revenue

Figure 8.15 FuMeiDa® (Hemoporfin): Sales Revenue

Figure 8.16 Levulan Kerastick®: Sales Revenue

Figure 8.17 Metvixia® (Metvix): Sales Revenue

Figure 8.18 Porfimer Sodium / Photofrin®: Sales Revenue

Figure 8.19 Verteporfin® (Visudyne): Sales Revenue

Figure 9.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2021

Figure 9.2 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2021

Figure 9.3 Clinical Trial Analysis: Distribution by Trial Phase

Figure 9.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase

Figure 9.5 Clinical Trial Analysis: Distribution by Trial Status

Figure 9.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Figure 9.7 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Status

Figure 9.8 Clinical Trial Analysis: Distribution by Target Patient Population

Figure 9.9 Clinical Trial Analysis: Distribution by Patient Gender

Figure 9.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Figure 9.11 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used

Figure 9.12 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted

Figure 9.13 Clinical Trial Analysis: Distribution by Type of Intervention Model

Figure 9.14 Clinical Trial Analysis: Distribution by Trial Purpose

Figure 9.15 Most Active Industry Players: Distribution by Number of Clinical Trials

Figure 9.16 Most Active Non-Industry Players: Distribution by Number of Clinical Trials

Figure 9.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography

Figure 9.18 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status

Figure 9.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Phase

Figure 9.20 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography

Figure 9.21 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status

Figure 10.1 Patent Analysis: Distribution by Type of Patent

Figure 10.2 Patent Analysis: Distribution by Patent Publication Year

Figure 10.3 Patent Analysis: Distribution by Type of Patent and Publication Year

Figure 10.4 Patent Analysis: Distribution by Patent Application Year

Figure 10.5 Patent Analysis: Distribution by Patent Jurisdiction

Figure 10.6 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant

Figure 10.7 Patent Analysis: Distribution by Patent Age

Figure 10.8 Patent Analysis: Distribution by CPC Symbols

Figure 10.9 Leading Industry Players: Distribution by Number of Patents

Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents

Figure 10.11 Leading Inventors: Distribution by Number of Patents

Figure 10.12 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players

Figure 10.13 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)

Figure 10.14 Light Activated Therapies: Patent Valuation

Figure 12.1 Global Light Activated Therapies Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035): Base Scenario (USD Million)

Figure 12.2 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)

Figure 12.3 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)

Figure 13.1 Photodynamic Therapy Market: Distribution by Target Indication

Figure 13.2 Photodynamic Therapy Market for Actinic Keratosis, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.3 Photodynamic Therapy Market for Prostate Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.4 Photodynamic Therapy Market for Age-related Macular Degeneration, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.5 Photodynamic Therapy Market for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.6 Photodynamic Therapy Market for Basal Cell Carcinoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.7 Photodynamic Therapy Market for Port Wine Stain, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.8 Photodynamic Therapy Market for Barrett’s Esophagus, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.9 Photodynamic Therapy Market for Esophageal Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.10 Photodynamic Therapy Market for Endobronchial Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.11 Photodynamic Therapy Market for Lung Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.12 Photodynamic Therapy Market for Bowen’s Disease, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.13 Photodynamic Therapy Market for Brain Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.14 Photodynamic Therapy Market for Bladder Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.15 Photodynamic Therapy Market for T-cell Lymphoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 13.16 Photodynamic Therapy Market for Urothelial Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 14.1 Photodynamic Therapy Market: Distribution by Therapeutic Area

Figure 14.2 Photodynamic Therapy Market for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 14.3 Photodynamic Therapy Market for Dermatological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 14.4 Photodynamic Therapy Market for Ophthalmic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.1 Photodynamic Therapy Market: Distribution by Key Geographical Regions

Figure 15.2 Photodynamic Therapy Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.3 Photodynamic Therapy Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.4 Photodynamic Therapy Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.5 Photodynamic Therapy Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.6 Photodynamic Therapy Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.7 Photodynamic Therapy Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.8 Photodynamic Therapy Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.9 Photodynamic Therapy Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.10 Photodynamic Therapy Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.11 Photodynamic Therapy Market in Rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.12 Photodynamic Therapy Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.13 Photodynamic Therapy Market in India, Forecasted Estimates (till 2035) (USD Million)

Figure 15.14 Photodynamic Therapy Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.15 Photodynamic Therapy Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.16 Photodynamic Therapy Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Figure 15.17 Photodynamic Therapy Market in Israel, Forecasted Estimates (till 2035) (USD Million)

Figure 15.18 Penetration Growth (P-G) Matrix: Key Geographical Regions

Figure 15.19 Market Movement Analysis: Key Geographical Regions

Figure 16.1 Concluding Remarks: Light Activated Therapy Developers

Figure 16.2 Concluding Remarks: Clinical Trial Analysis

Figure 16.3 Concluding Remarks: Patent Analysis

Figure 16.4 Concluding Remarks: Market Forecast and Opportunity Analysis

+ List of Table

Table 7.1 Light Activated Therapies: Information on Drug Pipeline, Type of Light Activated Therapy and Stage of Development

Table 7.2 Light Activated Therapies: Information on Type of Light Used, Type of Therapy, Dosing Frequency, Target Indication and Therapeutic Area

Table 7.3 Light Activated Therapy Developers: Information on Year of Establishment, Company Size and Location of Headquarters

Table 8.1 Light Activated Therapies: List of Companies Profiles

Table 8.2 ADVANZ PHARMA: Company Snapshot

Table 8.3 ADVANZ PHARMA: Product Portfolio

Table 8.4 ADVANZ PHARMA: Recent Developments and Future Outlook

Table 8.5 Biofrontera: Company Snapshot

Table 8.6 Biofrontera: Product Portfolio

Table 8.7 Biofrontera: Recent Developments and Future Outlook

Table 8.8 biolitec Pharma: Company Snapshot

Table 8.9 biolitec Pharma: Product Portfolio

Table 8.10 biolitec Pharma: Recent Developments and Future Outlook

Table 8.11 Luzitin: Company Snapshot

Table 8.12 Luzitin: Product Portfolio

Table 8.13 Luzitin: Recent Developments and Future Outlook

Table 8.14 Nanospectra Biosciences: Company Snapshot

Table 8.15 Nanospectra Biosciences: Product Portfolio

Table 8.16 Nanospectra Biosciences: Recent Developments and Future Outlook

Table 8.17 photoatomic: Company Snapshot

Table 8.18 photoatomic: Product Portfolio

Table 8.19 photoatomic: Recent Developments and Future Outlook

Table 8.20 Rakuten Medical: Company Snapshot

Table 8.21 Rakuten Medical: Product Portfolio

Table 8.22 Rakuten Medical: Recent Developments and Future Outlook

Table 8.23 Impact Biotech: Company Snapshot

Table 8.24 Impact Biotech: Product Portfolio

Table 8.25 Impact Biotech: Recent Developments and Future Outlook

Table 8.26 Theralase: Company Snapshot

Table 8.27 Theralase: Product Portfolio

Table 8.28 Theralase: Recent Developments and Future Outlook

Table 8.29 Cetuximab Sarotalocan®: Clinical Developmental Status

Table 8.30 Cetuximab Sarotalocan®: Clinical Trial Endpoints

Table 8.31 Cetuximab Sarotalocan®: Dosage Regimen

Table 8.32 Cetuximab Sarotalocan®: Key Insights

Table 8.33 Alacare®: Clinical Developmental Status

Table 8.34 Alacare®: Clinical Trial Endpoints

Table 8.35 Alacare®: Dosage Regimen

Table 8.36 Alacare®: Key Insights

Table 8.37 Ameluz®: Clinical Developmental Status

Table 8.38 Ameluz®: Clinical Trial Endpoints

Table 8.39 Ameluz®: Dosage Regimen

Table 8.40 Ameluz®: Key Insights

Table 8.41 Aminolevulinic Acid: Clinical Developmental Status

Table 8.42 Aminolevulinic Acid: Key Insights

Table 8.43 Foscan® (Temoporfin): Clinical Developmental Status

Table 8.44 Foscan® (Temoporfin): Clinical Trial Endpoints

Table 8.45 Foscan® (Temoporfin): Dosage Regimen

Table 8.46 Foscan® (Temoporfin): Key Insights

Table 8.47 FuMeiDa® (Hemoporfin): Clinical Developmental Status

Table 8.48 FuMeiDa® (Hemoporfin): Clinical Trial Endpoints

Table 8.49 FuMeiDa® (Hemoporfin): Dosage Regimen

Table 8.50 FuMeiDa® (Hemoporfin): Key Insights

Table 8.51 Levulan Kerastick®: Clinical Developmental Status

Table 8.52 Levulan Kerastick®: Clinical Trial Endpoints

Table 8.53 Levulan Kerastick®: Dosage Regimen

Table 8.54 Levulan Kerastick®: Key Insights

Table 8.55 Metvixia® (Metvix): Clinical Developmental Status

Table 8.56 Metvixia® (Metvix): Clinical Trial Endpoints

Table 8.57 Metvixia® (Metvix): Dosage Regimen

Table 8.58 Metvixia® (Metvix): Key Insights

Table 8.59 Porfimer Sodium / Photofrin®: Clinical Developmental Status

Table 8.60 Porfimer Sodium / Photofrin®: Clinical Trial Endpoints

Table 8.61 Porfimer Sodium / Photofrin®: Dosage Regimen

Table 8.62 Verteporfin® (Visudyne): Clinical Developmental Status

Table 8.63 Verteporfin® (Visudyne): Clinical Trial Endpoints

Table 8.64 Verteporfin® (Visudyne): Dosage Regimen

Table 8.65 Verteporfin® (Visudyne): Key Insights

Table 10.1 Patent Analysis: Top CPC Sections

Table 10.2 Patent Analysis: Top CPC Symbols

Table 10.3 Patent Analysis: Top CPC Codes

Table 10.4 Patent Analysis: Summary of Benchmarking Analysis

Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores

Table 10.6 Patent Analysis: List of Leading Patents (by Highest Relative Valuation)

Table 19.1 Light Activated Therapies: Distribution by Type of Light Activated Therapy

Table 19.2 Light Activated Therapies: Distribution by Stage of Development

Table 19.3 Light Activated Therapies: Distribution by Type of Light Used

Table 19.4 Light Activated Therapies: Distribution by Type of Therapy

Table 19.5 Light Activated Therapies: Distribution by Dosing Frequency

Table 19.6 Light Activated Therapies: Distribution by Target Indication

Table 19.7 Light Activated Therapies: Distribution by Therapeutic Area

Table 19.8 Light Activated Therapies: Distribution by Therapeutic Area and Stage of Development

Table 19.9 Light Activated Therapy Developers: Distribution by Year of Establishment

Table 19.10 Light Activated Therapy Developers: Distribution by Company Size

Table 19.11 Light Activated Therapy Developers: Distribution by Location of Headquarters (Region)

Table 19.12 Light Activated Therapy Developers: Distribution by Location of Headquarters (Country)

Table 19.13 ADVANZ PHARMA: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.14 Biofrontera: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.15 biolitec Pharma: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.16 Luzitin: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.17 Nanospectra Biosciences: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.18 photoatomic: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.19 Rakuten Medical: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.20 Impact Biotech: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.21 Theralase: Business Segment-wise Revenues and Consolidated Financial Details (USD Million), Since 2021

Table 19.22 Cetuximab Sarotalocan®: Sales Revenue

Table 19.23 Alacare®: Sales Revenue

Table 19.24 Ameluz®: Sales Revenue

Table 19.25 Aminolevulinic Acid: Sales Revenue

Table 19.26 Foscan® (Temoporfin): Sales Revenue

Table 19.27 FuMeiDa® (Hemoporfin): Sales Revenue

Table 19.28 Levulan Kerastick®: Sales Revenue

Table 19.29 Metvixia® (Metvix): Sales Revenue

Table 19.30 Porfimer Sodium / Photofrin®: Sales Revenue

Table 19.31 Verteporfin® (Visudyne): Sales Revenue

Table 19.32 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, since 2021

Table 19.33 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year, since 2021

Table 19.34 Clinical Trial Analysis: Distribution by Trial Phase

Table 19.35 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase

Table 19.36 Clinical Trial Analysis: Distribution by Trial Status

Table 19.37 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status

Table 19.38 Clinical Trial Analysis: Distribution of Patient Enrolled by Trial Status

Table 19.39 Clinical Trial Analysis: Distribution by Target Patient Population

Table 19.40 Clinical Trial Analysis: Distribution by Patient Gender

Table 19.41 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator

Table 19.42 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used

Table 19.43 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted

Table 19.44 Clinical Trial Analysis: Distribution by Type of Intervention Model

Table 19.45 Clinical Trial Analysis: Distribution by Trial Purpose

Table 19.46 Most Active Industry Players: Distribution by Number of Clinical Trials

Table 19.47 Most Active Non-Industry Players: Distribution by Number of Clinical Trials

Table 19.48 Clinical Trial Analysis: Distribution of Clinical Trials by Geography

Table 19.49 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status

Table 19.50 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Phase

Table 19.51 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography

Table 19.52 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status

Table 19.53 Patent Analysis: Distribution by Type of Patent

Table 19.54 Patent Analysis: Distribution by Patent Publication Year

Table 19.55 Patent Analysis: Distribution by Type of Patent and Publication Year

Table 19.56 Patent Analysis: Distribution by Patent Application Year

Table 19.57 Patent Analysis: Distribution by Patent Jurisdiction

Table 19.58 Patent Analysis: Cumulative Year-wise Trend by Type of Applicant

Table 19.59 Patent Analysis: Distribution by Patent Age

Table 19.60 Leading Industry Players: Distribution by Number of Patents

Table 19.61 Leading Non-Industry Players: Distribution by Number of Patents

Table 19.62 Leading Inventors: Distribution by Number of Patents

Table 19.63 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players

Table 19.64 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)

Table 19.65 Light Activated Therapies: Patent Valuation

Table 19.66 Global Photodynamic Therapy Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035): Base Scenario (USD Million)

Table 19.67 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)

Table 19.68 Global Photodynamic Therapy Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)

Table 19.69 Global Photodynamic Therapy Market: Distribution by Target Indication

Table 19.70 Photodynamic Therapy Market for Actinic Keratosis, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.71 Photodynamic Therapy Market for Prostate Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.72 Photodynamic Therapy Market for Age-related Macular Degeneration, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.73 Photodynamic Therapy Market for Head and Neck Squamous Cell Carcinoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.74 Photodynamic Therapy Market for Basal Cell Carcinoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.75 Photodynamic Therapy Market for Port Wine Stain, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.76 Photodynamic Therapy Market for Barrett’s Esophagus, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.77 Photodynamic Therapy Market for Esophageal Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.78 Photodynamic Therapy Market for Endobronchial Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.79 Photodynamic Therapy Market for Lung Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.80 Photodynamic Therapy Market for Bowen’s Disease, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.81 Photodynamic Therapy Market for Brain Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.82 Photodynamic Therapy Market for Bladder Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.83 Photodynamic Therapy Market for Urothelial Cancer, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.84 Photodynamic Therapy Market for T-cell Lymphoma, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.85 Photodynamic Therapy Market: Distribution by Therapeutic Area

Table 19.86 Photodynamic Therapy Market for Oncological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.87 Photodynamic Therapy Market for Dermatological Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.88 Photodynamic Therapy Market for Ophthalmic Disorders, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.89 Photodynamic Therapy Market: Distribution by Key Geographical Regions

Table 19.90 Photodynamic Therapy Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.91 Photodynamic Therapy Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.92 Photodynamic Therapy Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.93 Photodynamic Therapy Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.94 Photodynamic Therapy Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.95 Photodynamic Therapy Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.96 Photodynamic Therapy Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.97 Photodynamic Therapy Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.98 Photodynamic Therapy Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.99 Photodynamic Therapy Market in Rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.100 Photodynamic Therapy Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.101 Photodynamic Therapy Market in India, Forecasted Estimates (till 2035) (USD Million)

Table 19.102 Photodynamic Therapy Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.103 Photodynamic Therapy Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.104 Photodynamic Therapy Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035) (USD Million)

Table 19.105 Photodynamic Therapy Market in Israel, and Forecasted Estimates (till 2035) (USD Million)

+ List of Companies and Organizations

Please reach out to our team for more details.

Photodynamic Therapy Market